New drug cocktail aims to make ovarian tumors operable

NCT ID NCT07663513

Not yet recruiting Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a combination of two immunotherapy drugs (QL1706), a targeted therapy (bevacizumab), and standard chemotherapy can shrink advanced ovarian cancer before surgery. About 36 women with stage III-IV ovarian cancer will receive the treatment every 3 weeks, then undergo surgery to remove any remaining tumor. The main goal is to see how many achieve complete tumor removal.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Iparomlimab and tovorilimab (QL1706) combined with bevacizumab and chemotherapy (paclitaxel and carboplatin)
What this could lead to: If successful, this approach could shrink advanced ovarian tumors enough to allow complete surgical removal, potentially improving long-term outcomes.
What could go wrong: This is a small, early-phase study with only 36 participants and no comparison group. The combination may cause significant side effects, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer ovarian cancer ovarian serous adenocarcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCERS

Contacts and locations

Locations

Fudan university cancer hospital

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.